Login to Your Account



Pharma License Option Signed

PKAN Logs Retrophin $25M; Autism/Schizo Bid Lies Ahead, Too

By Randy Osborne
Staff Writer

Monday, August 19, 2013
With $25 million pledged from a stock sale to institutional investors, rare-disease specialist Retrophin Inc. signed a deal with an unidentified pharma firm for an option to license its autism/schizophrenia drug and said plans for a potentially pivotal trial are on track for RE-021, the firm's dual-acting receptor antagonist of angiotensin and endothelin receptors, as a therapy for focal segmental glomerulosclerosis (FSG).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription